CoChat

Sustained delivery of a HIF-1 antagonist for ocular neovascularization

Open access
Iwase, Takeshi, Fu, Jie, Yoshida, Tsunehiko, Muramatsu, Daisuke, Miki, Akiko, Hashida, Noriyasu, Lu, Lili, Oveson, Brian, Lima e Silva, Raquel, Seidel, Christopher, Yang, Ming, Connelly, Sheila, Shen, Jikui, Han, Bing, Wu, Mingsheng, Semenza, Gregg L., Hanes, Justin, Campochiaro, Peter A. · 2013 · Journal of Controlled Release
Cited by 75

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Doxorubicin (DXR) and daunorubicin (DNR) inhibit hypoxia-inducible factor-1 (HIF-1) transcriptional activity by blocking its binding to DNA. Intraocular injections of DXR or DNR suppressed choroidal and retinal neovascularization (NV), but also perturbed retinal function as demonstrated by electroretinograms (ERGs). DXR was conjugated to novel copolymers of branched polyethylene glycol and poly(sebacic acid) (DXR-PSA-PEG3) and formulated into nanoparticles that when placed in aqueous buffer, slowly released small DXR-conjugates. Intraocular injection of DXR-PSA-PEG3 nanoparticles (1 or 10 μg DXR content) reduced HIF-1-responsive gene products, strongly suppressed choroidal and retinal NV, and did not cause retinal toxicity. In transgenic mice that express VEGF in photoreceptors, intraocular injection of DXR-PSA-PEG3 nanoparticles (10 μg DXR content) suppressed NV for at least 35 days. Intraocular injection of DXR-PSA-PEG3 nanoparticles (2.7 mg DXR content) in rabbits resulted in sustained DXR-conjugate release with detectable levels in aqueous humor and vitreous for at least 105 days. This study demonstrates a novel HIF-1-inhibitor-polymer conjugate formulated into controlled-release particles that maximizes efficacy and duration of activity, minimizes toxicity, and provides a promising new chemical entity for treatment of ocular NV.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2013.10.008

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 7 references

Cited by

See all 75

Metadata

Authors
Iwase, T., Fu, J., Yoshida, T., Muramatsu, D., Miki, A., Hashida, N., Lu, L., Oveson, B., Lima e Silva, R., Seidel, C., Yang, M., Connelly, S., Shen, J., Han, B., Wu, M., Semenza, G. L., Hanes, J., & Campochiaro, P. A.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2013-12
Volume
172
Issue
3
Pages
625-633
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2114812216
Cited by
75
References
7
FWCI
2.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained delivery of a HIF-1 antagonist for ocular neovascularization. https://app.cochat.ai/papers/10.1016/j.jconrel.2013.10.008
The paper
Iwase, T., Fu, J., Yoshida, T., Muramatsu, D., Miki, A., Hashida, N., Lu, L., Oveson, B., Lima e Silva, R., Seidel, C., Yang, M., Connelly, S., Shen, J., Han, B., Wu, M., Semenza, G. L., Hanes, J., & Campochiaro, P. A. (2013). Sustained delivery of a HIF-1 antagonist for ocular neovascularization. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2013.10.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.